Feb 25th 2013 - Edison Investment Research today published a report on Mologen AG entitled "Innately Adaptive". In summary, the report says:
Mologen develops anti-cancer immune maintenance therapies aiming to give long-lasting responses. The investment case rests on a possible 2013 deal on the lead project, MGN1703, based on high-quality interim Phase II data. These indicated a 50% reduction in the hazard risk of disease progression when MGN1703 was dosed every three days. Mologen aims to partner MGN1703 to fund internal development of MGN1601, a cell-based vaccine for metastatic renal cancer. MGN1601 could be an orphan drug with no generic version possible; Mologen intends to sell direct.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »